natgillin/translations-raw huggingface dataset:
The virologic failure rate in patients treated with emtricitabine/tenofovir disoproxil fumarate + rilpivirine at Week 48 and Week 96 was 9.5% and 11.5% respectively, and 4.2% and 5.1% in the emtricitabine/tenofovir disoproxil fumarate + efavirenz arm. 
Stopa virološkog neuspjeha u bolesnika liječenih s emtricitabinom/tenofovirdizoproksil fumaratom + rilpivirinom u 48. i 96. tjednu iznosila je 9,5% odnosno 11,5%, te 4,2% i 5,1% u skupini koja prima emtricitabin/tenofovirdizoproksilfumarat + efavirenz.
Fifty-two percent of HIV-1 isolates with emergent resistance in the rilpivirine arm developed concomitant NNRTI and NRTI mutations, most frequently E138K and M184V. 
Pedeset dva postotka HIV-1 izolata s novonastalom rezistencijom u skupini liječenoj rilpivirinom razvilo je istodobne NNRTI i NRTI mutacije, najčešće E138K i M184V.
Discontinued due to adverse event (AE) 
Prekid zbog štetnog događaja
Tenofovir is renally eliminated by both glomerular filtration and active tubular secretion. 
Tenofovir se eliminira bubrezima putem glomerularne filtracije i aktivne tubularne sekrecije.
Odefsey should be used with caution in patients with moderate hepatic impairment. 
Odefsey se treba oprezno koristiti u pacijenata s umjerenim oštećenjem funkcije jetre.
Lower exposures of rilpivirine (one of the components of Odefsey) were observed during pregnancy; therefore viral load should be monitored closely. 
Tijekom trudnoće opažene su manje izloženosti rilpivirinu (jedna od komponenti lijeka Odefsey); stoga je potrebno pažljivo pratiti virusno opterećenje.
Also, emtricitabine did not inhibit uridine-5'-diphosphoglucuronyl transferase (UGT), the enzyme responsible for glucuronidation. 
Osim toga, emtricitabin nije inhibirao uridin-5'-difosfoglukuronil transferazu (UGT), enzim odgovoran za glukuronidaciju.
The safety and efficacy of Odefsey in patients with significant underlying liver disorders have not been established. 
Sigurnost i djelotvornost primjene lijeka Odefsey u bolesnika s podležećim značajnim bolestima jetre nisu ustanovljene.
Some medicinal products should not be co-administered with Odefsey (see sections 4.3 and 4.5). 
Neki lijekovi ne smiju se primjenjivati istodobno s lijekom Odefsey (vidjeti dijelove 4.3 i 4.5).
 If you are taking any of these medicines, do not take Odefsey and tell your doctor immediately. 
Ako uzimate bilo koji od ovih lijekova, nemojte uzimati lijek Odefsey i odmah o tome obavijestite svog liječnika.
• Medicines for stomach ulcers, heartburn or acid reflux such as: 
• Lijekove za čireve želuca i dvanaesnika, žgaravicu ili gastroezofagealnu refluksnu bolest poput:
Overall response (HIV-1 RNA < 50 copies/mL (TLOVRa))b 
Ukupni odgovor (HIV-1 RNK < 50 kopija/ml (TLOVRa))b
Grey, capsule-shaped, film-coated tablets, of dimensions 15 mm x 7 mm, debossed with “GSI” on one side of the tablet and “255” on the other side of the tablet. 
Siva filmom obložena tableta u obliku kapsule veličine 15 mm x 7 mm, s utisnutom oznakom „GSI” na jednoj strani tablete i „255” na drugoj strani tablete.
Tenofovir alafenamide is transported by P-gp and breast cancer resistance protein (BCRP). 
Tenofoviralafenamid se transportira P-glikoproteinom (P-gp) i proteinom rezistencije karcinoma dojke (BCRP).
antacids (aluminium/magnesium hydroxide or calcium carbonate) 
Antacidi (npr. aluminijev ili magnezijev hidroksid, kalcijev karbonat)
N/A = not applicable 1 This interaction study has been performed with a dose higher than the recommended dose for rilpivirine hydrochloride assessing the maximal effect on the co-administered medicinal product. 
1 Ovo ispitivanje interakcije provedeno je s dozom većom od preporučene doze za rilpivirinklorid i utvrđen je maksimalni učinak na istodobno primijenjeni lijek.
Bone toxicity was observed as reduced bone mineral density in rats and dogs at tenofovir exposures at least four times greater than those expected after administration of Odefsey. 
Toksičnost za kosti uočena je kao smanjena mineralna gustoća kostiju u štakora i pasa pri izloženostima tenofoviru najmanje četiri puta većima od onih očekivanih nakon primjene lijeka Odefsey.
For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. 
Za praćenje lipida i glukoze u krvi preporučuju se utvrđene smjernice za liječenje HIV-a.
• St. John's wort (Hypericum perforatum) 
• gospinu travu (Hypericum perforatum).
The pharmacokinetic exposure of rilpivirine in co-infected patients was comparable to that in patients without co-infection. 
Farmakokinetička izloženost rilpivirinu u bolesnika istodobno zaraženih bila je usporediva s izloženošću u bolesnika bez istodobne infekcije.
Contains lactose (as monohydrate), see leaflet for further information. 
POPIS POMOĆNIH TVARI Sadrži laktozu (u obliku hidrata), za dodatne informacije vidjeti uputu o lijeku.
• low platelet count (a type of blood cell involved in clotting blood) 
• mali broj krvnih pločica (tip krvnih stanica koje sudjeluju u zgrušavanju krvi)
In virologically suppressed patients 
Virološki suprimirani odrasli bolesnici u Ispitivanju
Co-administration of Odefsey with other medicinal products that inhibit P-gp and BCRP activity (e.g., ketoconazole, fluconazole, itraconazole, posaconazole, voriconazole, ciclosporin) is expected to increase the absorption and plasma concentration of tenofovir alafenamide. 
Očekuje se da će istodobna primjena lijeka Odefsey s drugim lijekovima koji inhibiraju aktivnost P-gp-a i BCRP-a (npr. ketokonazol, flukonazol, itrakonazol, posakonazol, vorikonazol, ciklosporin) povećati apsorpciju i koncentraciju tenofoviralafenamida u plazmi.
No clinically relevant pharmacokinetic differences due to age, gender or ethnicity have been identified for emtricitabine, rilpivirine or tenofovir alafenamide. 
Klinički značajne farmakokinetičke razlike vezane uz dob, spol ili etničku pripadnost nisu ustanovljene za emtricitabin, rilpivirin ili tenofoviralafenamid.
CYP enzyme inhibitors 
Inhibitori CYP enzima
Patients should be informed that fatigue, dizziness and somnolence have been reported during treatment with the components of Odefsey (see section 4.8). 
Bolesnike treba obavijestiti da su tijekom liječenja komponentama lijeka Odefsey zabilježeni umor, omaglica i somnolencija (vidjeti dio 4.8).
Odefsey should not be co-administered with medicinal products that can result in significant decreases in rilpivirine plasma concentrations (due to cytochrome P450 [CYP]3A enzyme induction or gastric pH increase), which may result in loss of therapeutic effect of Odefsey (see section 4.5), including: 
Odefsey se ne smije primjenjivati istodobno s lijekovima koji mogu dovesti do značajnog smanjenja koncentracije rilpivirina u plazmi (zbog indukcije enzima citokroma P450 [CYP]3A ili povećanja želučane pH-vrijednosti), što može rezultirati gubitkom terapijskog učinka lijeka Odefsey (vidjeti dio 4.5), uključujući:
Odefsey should not be co-administered with other medicinal products containing tenofovir alafenamide, lamivudine, tenofovir disoproxil or adefovir dipivoxil (see section 4.5). 
Odefsey se ne smije primijeniti istodobno s drugim lijekovima koji sadrže tenofoviralafenamid, lamivudin, tenofovirdizoproksil ili adefovirdipivoksil (vidjeti dio 4.5).
In Studies GS-US-292-0104 and GS-US-292-0111, the rate of virologic success was similar across patient subgroups (age, gender, race, baseline HIV-1 RNA, or baseline CD4+ cell count). 
U ispitivanjima GS-US-292-0104 i GS-US-292-0111, stopa virološkog uspjeha bila je slična kod svih podskupina bolesnika (dob, spol, rasa, početna HIV-1 RNK, ili početni broj CD4+ stanica).
abdominal pain1, 3, vomiting1, 3, increased lipase1, abdominal discomfort1, dry mouth1, flatulence3, diarrhoea3 
bol u abdomenu1,3, povraćanje1,3, povišena lipaza1, nelagoda u abdomenu1, suha usta1, flatulencija3, proljev3
FTC = emtricitabine; TAF = tenofovir alafenamide; TFV = tenofovir, N/A = not applicable Data are presented as mean (%CV). 
FTC = emtricitabin; TAF = tenofoviralafenamid; TFV = tenofovir, N/P = nije primjenjivo
Considering all of the available in vitro data and data generated in treatment-naïve patients, the following resistance-associated mutations in HIV-1 RT, when present at baseline, may affect the activity of Odefsey: K65R, K70E, K101E, K101P, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, M184I, M184V, Y188L, H221Y, F227C, M230I, M230L and the combination of L100I and K103N. 
Uzimajući u obzir sve dostupne in vitro podatke i podatke generirane u bolesnika koji nisu bili prethodno liječeni, sljedeće mutacije u HIV-1 RT koje su povezane s rezistencijom, kada postoje na početku, mogu utjecati na aktivnost lijeka Odefsey: K65R, K70E, K101E, K101P, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, M184I, M184V, Y188L, H221Y, F227C, M230I, M230L i kombinacija L100I i K103N.
No dose adjustment of Odefsey is required in patients with mild (Child Pugh Class A) or moderate (Child Pugh Class B) hepatic impairment. 
Nije potrebna prilagodba doze lijeka Odefsey u bolesnika s blagim (Child Pugh, stadij A) ili umjerenim (Child Pugh stadij B) oštećenjem funkcije jetre.
Table 5: Virologic outcomes of Studies GS-US-366-1216 and GS-US-366-1160 at Weeks 48a and 
Tablica 5: Virološki ishodi u ispitivanjima GS-US-366-1216 i GS-US-366-1160 u 48. tjednua i 96. tjednub
If Odefsey is stopped for any reason, speak to your doctor before you restart taking Odefsey tablets. 
Ako zbog bilo kojeg razloga prestanete uzimati lijek Odefsey, porazgovarajte s liječnikom prije nego što ponovno počnete uzimati tablete lijeka Odefsey.
If you are taking an antacid such as aluminium/magnesium hydroxide, or calcium carbonate, take it at least 2 hours before or at least 4 hours after Odefsey. 
Ako uzimate antacid kao što je aluminijev/magnezijev hidroksid, ili kalcijev karbonat, uzmite ga najmanje 2 sata prije ili najmanje 4 sata nakon uzimanja lijeka Odefsey.
Odefsey should not be co-administered with other antiretroviral medicinal products (see section 4.5). 
Odefsey se ne smije primjenjivati istodobno s drugim antiretrovirusnim lijekovima (vidjeti dio 4.5).
Over 96 weeks of treatment with rilpivirine mean changes of 0.1 mg/dL (range: -0.3 mg/dL to 0.6 mg/dL) for creatinine and -13.3 mL/min/1.73 m2 (range: -63.7 mL/min/1.73 m2 to 40.1 mL/min/1.73 m2) for eGFR were observed. 
Tijekom 96. tjedana liječenja rilpivirinom, uočene su srednje vrijednosti promjene od 0,1 mg/dl (raspon: -0,3 mg/dl do 0,6 mg/dl) za kreatinin i -13,3 ml/min/1,73 m2 (raspon: -63,7 ml/min/1,73 m2 do 40,1 ml/min/1,73 m2) za eGFR.
High density polyethylene (HDPE) bottle with a polypropylene continuous-thread, child-resistant cap, lined with an induction activated aluminium foil liner containing 30 film-coated tablets. 
Boca od polietilena visoke gustoće (HDPE) s polipropilenskim zatvaračem sigurnim za djecu s kontinuiranim navojem, otvora prekrivenog aluminijskom folijom koja, koja sadrži 30 filmom obloženih tableta.
Odefsey has not been studied in patients with severe hepatic impairment (Child Pugh Class C); therefore, Odefsey is not recommended for use in patients with severe hepatic impairment (see sections 4.4 and 5.2). 
Odefsey nije ispitan u bolesnika s teškim oštećenjem funkcije jetre (Child Pugh stadij C) te se stoga primjena lijeka Odefsey ne preporučuje u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dijelove 4.4 i 5.2).
b In both studies, patients were stratified by baseline HIV-1 RNA (≤ 100,000 copies/mL, > 100,000 copies/mL to ≤ 400,000 copies/mL, or > 400,000 copies/mL), by CD4+ cell count (< 50 cells/µL, 50-199 cells/µL, or ≥ 200 cells/µL), and by region (US or ex US). 
U oba ispitivanja bolesnici su stratificirani prema početnoj HIV-1 RNK (≤ 100 000 kopija/ml, > 100 000 kopija/ml do ≤ 400.000 kopija/ml, ili > 400.000 kopija/ml), prema broju CD4+ stanica (< 50 stanica/µl, 50-199 stanica/µl ili ≥ 200 stanica/µl) te po regiji (SAD ili izvan SAD-a).
In patients who entered the studies with mild or moderate renal impairment, the serum creatinine increase observed was similar to that seen in patients with normal renal function. 
U bolesnika koji su ušli u ispitivanja s blagim do umjerenim oštećenjem funkcije bubrega, uočeno povećanje serumskog kreatinina bilo je slično onome viđenog u bolesnika s normalnom funkcijom bubrega.
Rilpivirine is a diarylpyrimidine NNRTI of HIV-1. 
Rilpivirin je diarilpirimidin NNRTI virusa HIV-1.
Table 3: Virologic outcomes of Studies GS-US-292-0104, GS-US-292-0111 at Week 48 and Week 144a, and GS-US-292-0109 at Week 48a 
Tablica 3: Virološki ishodi u ispitivanjima GS-US-292-0104, GS-US-292-0111 u 48. i 144. tjednua i GS-US-292-0109 u 48. tjednua
Co-administration of Odefsey with medicinal products that inhibit CYP3A enzyme activity has been observed to increase rilpivirine plasma concentrations. 
Uočeno je da istodobna primjena lijeka Odefsey s lijekovima koji inhibiraju aktivnost CYP3A enzima povećava koncentracije rilpivirina u plazmi.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3) with the components of Odefsey. 
Ispitivanja na životinjama ne ukazuju na izravan ili neizravan štetan učinak komponenata lijeka Odefsey u odnosu na reproduktivnu toksičnost (vidjeti dio 5.3).
The antiviral activity of emtricitabine against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI CCR5 cell line, and PBMCs. 
Antivirusna aktivnost emtricitabina protiv laboratorijskih i kliničkih izolata virusa HIV-1 procijenjena je na limfoblastoidnim staničnim linijama, staničnoj liniji MAGI CCR5 i PBMC.
Odefsey should be used with caution when co-administered with a medicinal product with a known risk of Torsade de Pointes (see section 4.4). 
Odefsey se treba oprezno koristiti kada se primjenjuje istodobno s lijekom koji nosi poznati rizik od torsade de pointes (vidjeti dio 4.4).
In a separate Phase 1 study of emtricitabine alone, mean systemic emtricitabine exposure was higher in patients with severe renal impairment (estimated CrCl < 30 mL/min) (33.7 µg•h/mL) than in subjects with normal renal function (11.8 µg•h/mL). 
U zasebnom ispitivanju faze I u kojem se ispitivao samo emtricitabin, srednja vrijednost sistemske izloženosti emtricitabinu bila je viša u bolesnika s teškim oštećenjem funkcije bubrega (procijenjeni CrCl < 30 ml/min) (33,7 µg•h/ml) nego u ispitanika s normalnom funkcijom bubrega (11,8 µg•h/ml).
Hepatitis B and/or hepatitis C virus co-infection The pharmacokinetics of emtricitabine, rilpivirine and tenofovir alafenamide have not been fully evaluated in patients co-infected with hepatitis B and/or C virus. 
Istodobna infekcija virusom hepatitisa B i/ili hepatitisa C Farmakokinetika emtricitabina i tenofoviralafenamida nije potpuno procijenjena u bolesnika koji su istodobno zaraženi virusom hepatitisa B i/ili C.
Patients with liver disease including chronic hepatitis B or C, who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications. 
Bolesnici s bolešću jetre, uključujući kronični hepatitis B ili C, koji se liječe antiretrovirusnim lijekovima, izloženi su većemu riziku od teških i potencijalno po život opasnih jetrenih komplikacija.
In patients co-infected with hepatitis B or C virus receiving rilpivirine, the incidence of hepatic enzyme elevation was higher than in patients receiving rilpivirine who were not co-infected. 
U bolesnika istodobno zaraženih virusom hepatitisa B ili C koji primaju rilpivirin, incidencija porasta koncentracije enzima jetre bila je veća nego u bolesnika koji primaju rilpivirin i koji nisu bili istodobno zaraženi.
A risk for increases in dabigatran plasma concentrations cannot be excluded (inhibition of intestinal P-gp). 
Ne može se isključiti rizik od povećanja koncentracija dabigatrana u plazmi (inhibicija crijevnog P-gp).
The mean change from baseline in CD4+ cell count at Week 48 was -2 cells/mm3. 
Srednja vrijednost promjene od početne vrijednosti u broju stanica CD4+ u 48. tjednu bila je -2 stanice/mm3.
Tenofovir alafenamide is a substrate of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 in vitro. 
Tenofoviralafenamid je supstrat transportnog polipeptida za organske anione (OATP) 1B1 i OATP1B3 in vitro.
c P-value for the superiority test comparing the percentages of virologic success was from the CMH (Cochran-Mantel-Haenszel) test stratified by the prior treatment regimen (EFV/FTC/TDF, FTC/TDF plus boosted atazanavir, or E/C/F/TDF). 
c P-vrijednost za test superiornosti kojim su uspoređeni postotci virološkog uspjeha iz CMH (Cochran-Mantel-Haenszel) testa stratificirano prema prethodnom režimu liječenja (EFV/FTC/TDF, FTC/TDF plus pojačani atazanavir ili E/C/F/TDF).
In human clinical studies, a 10 mg oral dose of tenofovir alafenamide given with emtricitabine, cobicistat and elvitegravir resulted in tenofovir diphosphate concentrations > 4-fold higher in PBMCs and > 90% lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil (as fumarate) given with emtricitabine, cobicistat and elvitegravir. 
U kliničkim ispitivanjima u ljudi, peroralna doza od 10 mg tenofoviralafenamida primijenjenog s emtricitabinom, kobicistatom i elvitegravirom rezultirala je koncentracijama tenofovirdifosfata za > 4 puta većima u PBMC-ovima i > 90% manjim koncentracijama tenofovira u plazmi u usporedbi s peroralnom dozom tenofovirdizoproksila (u obliku fumarata) od 245 mg primijenjenog s emtricitabinom, kobicistatom i elvitegravirom.
The most frequently reported adverse reactions in clinical studies of treatment-naïve patients taking emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat were nausea (11%), diarrhoea (7%), and headache (6%). 
Najčešće zabilježene nuspojave u kliničkim ispitivanjima u bolesnika koji prethodno nisu bili liječeni i primali su emtricitabin + tenofoviralafenamid u kombinaciji s elvitegravirom + kobicistatom bile su mučnina (11%), proljev (7%) i glavobolja (6%).
• stomach pain or discomfort 
• bol u trbuhu ili nelagodu
Do not breast-feed during treatment with Odefsey. 
Nemojte dojiti tijekom liječenja lijekom Odefsey.
 If this applies to you, do not take Odefsey and tell your doctor immediately. 
Ako se ovo odnosi na Vas, nemojte uzimati lijek Odefsey i odmah o tome obavijestite liječnika.
Table 6: Pharmacokinetics of emtricitabine and tenofovir alafenamide in antiretroviral-naïve adolescents and adults 
Tablica 6: Farmakokinetika emtricitabina i tenofoviralafenamida u adolescenata i odraslih koji prethodno nisu bili liječeni antiretrovirusnim lijekovima
The pharmacokinetics, safety, tolerability, and efficacy of rilpivirine 25 mg once daily, in combination with an investigator-selected BR containing two NRTIs, were evaluated in Study TMC278-C213, a single-arm, open-label Phase 2 study in antiretroviral-naïve HIV-1 infected paediatric patients 12 to < 18 years of age and weighing at least 32 kg. 
Farmakokinetika, sigurnost, tolerabilnost i djelotvornost rilpivirina u dozi od 25 mg jedanput na dan, u kombinaciji s BR-om odabranim od strane ispitivača, koji sadrži dva NRTI-a, procijenjeni su u Ispitivanju TMC278-C213, otvorenom ispitivanju faze 2 s jednom skupinom u pedijatrijskih bolesnika zaraženih virusom HIV-1 koji prethodno nisu bili antiretrovirusno liječeni u dobi od 12 do < 18 godina s tjelesnom težinom od najmanje 32 kg.
In a study comparing 8 patients with mild hepatic impairment (Child-Pugh Class A) to 8 matched controls and 8 patients with moderate hepatic impairment (Child-Pugh Class B) to 8 matched controls, the multiple dose exposure of rilpivirine was 47% higher in patients with mild hepatic impairment and 5% higher in patients with moderate hepatic impairment. 
U ispitivanju u kojem se pravila usporedba 8 bolesnika s blagim oštećenjem funkcije jetre (Child-Pugh, stadij A) s 8 odgovarajućih kontrola i 8 bolesnika s umjerenim oštećenjem funkcije jetre (Child-Pugh, stadij B) s 8 odgovarajućih kontrola, izloženost kod višekratnog doziranja rilpivirina bila je 47% veća u bolesnika s blagim oštećenjem funkcije jetre i 5% veća u bolesnika s umjerenim oštećenjem funkcije jetre.
Tenofovir diphosphate inhibits HIV RT, resulting in DNA chain termination. 
Tenofovir difosfat inhibira HIV reverznu transkriptazu (RT), što rezultira u prekidu lanca DNK.
As with other antiretroviral medicinal products, resistance testing and/or historical resistance data should guide the use of Odefsey (see section 4.4). 
Kao kod drugih antiretrovirusnih lijekova, liječenje lijekom Odefsey treba se voditi na temelju ispitivanja rezistencije i/ili podataka o rezistenciji u povjesti bolesti (vidjeti dio 4.4).
Odefsey should be used with caution when co-administered with medicinal products with a known risk of Torsade de Pointes. 
Odefsey se treba oprezno koristiti kada se primjenjuje istodobno s lijekovima koji nose poznati rizik od torsade de pointes.
Treatment-naïve adults in Studies GS-US-292-0104 and GS-US-292-0111b 
Odrasli bolesnici koji prethodno nisu bili liječeni u ispitivanjima GS-US-292-0104 i GS-US-292-0111b
These medicines can increase the amount of rilpivirine and tenofovir alafenamide (components of Odefsey) in your blood. 
Ti lijekovi mogu povećati količinu rilpivirina i tenofoviralafenamida (komponente lijeka Odefsey) u Vašoj krvi.
dexamethasone (a corticosteroid medicine used to treat inflammation and suppress the immune system) when taken by mouth or injected (except as a single dose treatment) products that contain St. John's wort (Hypericum perforatum) (a herbal remedy used for depression and anxiety) 
deksametazon (kortikosteroidni lijek koji se koristi za liječenje upala i suprimiranje (smanjivanje aktivnosti) imunološkog sustava) kada se uzima kroz usta ili se ubrizgava (osim kod liječenja primjenom jednokratne doze) proizvodi koji sadržavaju gospinu travu (Hypericum perforatum) (biljni lijek koji se primjenjuje za depresiju i tjeskobu)
Clinically relevant changes in the pharmacokinetics of tenofovir alafenamide or its metabolite tenofovir were not observed in patients with mild or moderate hepatic impairment. 
Nisu zapažene klinički važne promjene u farmakokinetici tenofoviralafenamida ili njegova metabolita tenofovira u bolesnika s blagim ili umjerenim oštećenjem funkcije jetre.
Proportion (%) of patients with HIV-1 RNA < 50 copies/mL by prior treatment regimend EFV/FTC/TDF FTC/TDF plus boosted atazanavir E/C/F/TDF 
Udio (%) bolesnika s HIV-1 RNK < 50 kopija/ml na prvotnom režimu liječenjad EFV/FTC/TDF FTC/TDF plus pojačani atazanavir E/C/F/TDF
The safety of emtricitabine + tenofovir alafenamide has not been established in patients with severe renal impairment (estimated CrCl ≥ 15 mL/min and < 30 mL/min). 
Sigurnost emtricitabina + tenofoviralafenamida nije ustanovljena u bolesnika s teškim oštećenjem funkcije bubrega (procijenjeni CrCl ≥ 15 ml/min i < 30 ml/min).
Median (Q1, Q3) change from baseline at Week 144 in total cholesterol to HDL-cholesterol ratio was 0.2 (-0.3, 0.7) in patients receiving FTC + TAF and 0.1 (-0.4, 0.6) in patients receiving FTC + TDF (p = 0.006 for the difference between treatment groups). 
Medijan (Q1, Q3) promjene omjera ukupnog kolesterola i HDL kolesterola od početne vrijednosti u 144. tjednu bio je 0,2 (-0,3; 0,7) u bolesnika koji su primali FTC + TAF i 0,1 (-0,4; 0,6) u bolesnika koji su primali FTC + TDF (p = 0,006 za razliku između liječenih skupina).
The median increase from baseline for these parameters was greater in patients receiving FTC + TAF compared with patients receiving FTC + TDF (p < 0.001 for the difference between treatment groups for fasting total cholesterol, direct LDL- and HDL-cholesterol, and triglycerides). 
Medijan povećanja ovih parametara od početnih vrijednosti bio je veći u bolesnika koji su primali FTC + TAF u usporedbi s bolesnicima koji su primali FTC + TDF (p < 0,001 za razliku između liječenih skupina u vrijednostima ukupnog kolesterola, LDL i HDL kolesterola te triglicerida natašte).